Imagine a twelve-year-old sitting with a parent in a Colorado clinic waiting room, discussing a weekly injection that could alter their health trajectory and possibly their whole relationship with their body for years or decades to come. The dialogue taking place in those exam rooms is not straightforward, and this scene is becoming more and more common throughout the United States. They include long-term unknowns, clinical data, ethical ambiguity, and a medication that, according to any fair analysis of the data, performs remarkably well. Pediatric medicine is still debating whether “works well” is a good enough reason to prescribe it to a developing adolescent, and opinions are more divided than headlines often indicate.
In late 2022, the FDA approved Wegovy, the brand name for semaglutide at the weight-management dosage, for use in adolescents 12 years of age and older. It is hard to discount the clinical trial data supporting that approval. In a 68-week study with 201 obese teenagers, the average BMI decreased by 16.1% for those who used Wegovy in addition to lifestyle counseling.
| Topic | Wegovy (Semaglutide) for Adolescents — Benefits, Risks & Ethical Debate |
|---|---|
| Drug Name | Wegovy (semaglutide injection) |
| Manufacturer | Novo Nordisk |
| Mechanism | Mimics GLP-1 hormone, controlling appetite and cravings; weekly subcutaneous injection |
| FDA Approval for Adolescents | December 2022 — approved for ages 12+ with obesity (BMI ≥95th percentile) |
| AAP Guideline | January 2023 — American Academy of Pediatrics recommended offering obesity medications as adjunct to lifestyle treatment |
| Clinical Trial Results | 201 adolescents (ages 12–17); 68 weeks; average BMI reduction of 16.1% vs. 0.6% increase in placebo group |
| Nearly 45% of kids | Dropped below obesity BMI baseline in trial (University of Minnesota analysis) |
| Weight Regain Risk | Stopping Wegovy generally leads to weight regain |
| US Adolescent Obesity Rate | ~1 in 5 US adolescents (approx. 15 million children) |
| Prescription Rate (2023) | Less than 1% of adolescents with obesity received any obesity medication prescription |
| Racial Disparity | Black adolescents 39% less likely to be prescribed than White adolescents, despite 27% higher severe obesity rate |
| Known Serious Risks | Gastroparesis, pancreatitis, gallbladder disease, thyroid C-cell tumors (from adult studies) |
| Key Concern | Unknown long-term effects on developing bodies; potential lifelong dependency |
| Key Advocate | Dr. Megan Kelsey, Children’s Hospital Colorado; Dr. Aaron Kelly, University of Minnesota |
| Reference Website | CDC — Adolescent Obesity Medication Prescriptions Report |
The average BMI increased by 0.6% in the placebo group, which only received lifestyle counseling. Almost 45% of the teenagers taking semaglutide completely fell below the obesity threshold. The medication seems to be even more effective in children than in adults, a finding that calls for further research but has clear ramifications for how the medical community should view early intervention. Bariatric surgery, which is significantly more invasive and has significant risks of its own, is the only treatment with a better track record.
Having treated children with obesity for a long time, Megan Kelsey, medical director of lifestyle medicine and adolescent bariatric surgery at Children’s Hospital Colorado, has witnessed changes in the field’s thinking that have occasionally taken her by surprise. She acknowledges that early in her career, she had a less thorough understanding of the condition than she does now. Like many others, she was more likely to blame personal decisions than the complex web of genetic, physiological, socioeconomic, and environmental factors that research has since revealed.
The argument against medicating children frequently carries an implicit assumption that lifestyle modifications alone should be sufficient, that willpower and improved habits are the appropriate tools for the job, which makes evolution important for the Wegovy debate. A more nuanced picture is revealed by the evidence gathered over years of working with patients for whom those tools were insufficient. Many people believe that obesity in children will go away. Contrary to what the data indicates, untreated childhood obesity can lead to high blood pressure, type 2 diabetes, liver disease, sleep apnea, and an increased risk of dying young from any cause.
However, clinicians’ reluctance is not unreasonable. In the context of developing bodies, the major risks reported in adult studies—such as gastroparesis, pancreatitis, gallbladder disease, and uncommon thyroid C-cell tumors—are still being evaluated.
Another issue is what it really means to stop using drugs. Adolescents in the clinical trials typically gained weight back when they stopped taking Wegovy. This raises an unsettling question: are we giving kids a treatment or a lifelong dependency? It’s more a feature of how obesity functions as a chronic illness than a flaw in the medication. It’s possible that the answer is both—that long-term use is medically acceptable for some teenagers in the same way that a diabetic patient requires insulin indefinitely—but that framing necessitates a degree of candor about managing chronic diseases that the public discourse hasn’t yet reached.
Observing the prescription data, it seems as though the clinical system is proceeding cautiously enough to raise its own concerns. Less than 1% of adolescents with obesity were prescribed any obesity medication in 2023, despite the FDA’s approval and the American Academy of Pediatrics’ January 2023 guideline recommending obesity medications as part of evidence-based adolescent treatment.
When you consider the baseline against which it is measured, the 300% relative increase that year seems dramatic. 83% of the 427 teenagers who were prescribed obesity medication in 2023 had severe obesity, class 2 or class 3, indicating that many doctors are saving the medication for situations where it is most difficult to dispute the medical necessity. This caution makes sense, but it also implies that many younger adolescents with moderate obesity—who could greatly benefit from early intervention—are not receiving treatment.
It is more difficult to justify and explain the discrepancies ingrained in those prescription patterns. In 2023, Black adolescents were 39% less likely to be prescribed an obesity medication, despite having a 27% higher rate of severe obesity than White adolescents. Although each of the contributing factors—insurance gaps, prior authorization barriers, drug shortages, cost, and variations in provider practice—is well-documented, they haven’t been addressed collectively. It’s still unclear if structural barriers are strong enough to endure in spite of clinical recommendations, or if the gap is closing as awareness of the AAP guideline grows. For various reasons, both scenarios are worrisome.
The Wegovy debate for children is fundamentally about how medicine should treat chronic illness in individuals whose bodies are still developing, whose identities are still forming, and whose relationship with their own weight is being shaped in real time by the culture surrounding them. The clinical question is not made easier by any of those factors.
The medication is effective. Although there are risks, they are usually controllable. There are well-established costs associated with the alternative, which is to ignore teenage obesity in the hopes that something will change. What is certain is that the discussion must take place in public and in clinic settings, with the full weight of the evidence presented, and without the moralizing that has historically made treating childhood obesity more difficult than it needs to be.
